Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: Meta-analysis of randomized controlled trials

Diabetes Care

Volumn 35, Issue 12, 2012, Pages 2698-2705

  Esposito, Katherine ^a   Chiodini, Paolo ^a   Capuano, Annalisa ^a   Petrizzo, Michela ^a   Improta, Maria Rosaria ^a   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; BEDTIME DOSAGE; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; MORNING DOSAGE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84869792188     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0698     Document Type: Article

References (24)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321
2. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
3. National Committee for Quality Assurance. The state of health care quality [article online], 2010. Washington, DC, National Committee for Quality Assurance. Available from http://www.ncqa.org/portals/0/ state%20of%20health%20care/2010/sohc%202010%20-%20full2.pdf. Accessed 14 February 2012
4. Cimino A, Fava D, Giorda C, et al. AMD annals 2010: quality indicators of diabetes care in Italy [article online], 2010. Available from http://www.infodiabetes.it/files/Annali-2010-inglese-II.pdf. Accessed 29 February 2012
5. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
6. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Timeaction profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649 (Pubitemid 30321545)
7. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-1112 (Pubitemid 40616620)
8. Hompesch M, Ocheltree SM, Wondmagegnehu ET, et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009;25:2679-2687
9. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPHinsulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD005613
10. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;7:CD006383
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W94
12. Higgins JPT, Green S, Eds. Cochrane handbook for systematic reviews of interventions version 5.0.0 [Internet], 2008. Available from www.cochrane-handbook. org. Accessed 14 February 2012
13. Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-1132
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558 (Pubitemid 34746062)
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188 (Pubitemid 17189972)
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
17. Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010;12:916-922
18. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober SA. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabet Med 2010;27:181-188
19. Arakaki RF, Blevins TC, Liljenquist DR, et al. Efficacy and safety of insulin lispro protamine suspension versus insulin glargine added to oral antihyperglycemic medications and exenatide in patients with type 2 diabetes (abstract). Diabetologia 2010; 53(Suppl. 1):S-390
20. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-539
21. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
22. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 2011;34:510-517
23. Peyrot M, Rubin RR, Lauritzen T, et al.; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the crossnational Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679 (Pubitemid 43951158)
24. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010; 33:733-735